News

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

Day of Dravet, a 1-day virtual event on Saturday, October 17th will give attendees an opportunity to meet industry representatives and ask questions.

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, discuss their experience with EpiTRAQ and the role it can play in optimizing the epilepsy care transition.

The new center is part of the first cohort of centers nationally to receive this new NIH funding and is the first and only in Nevada.

The 7th International LGS Foundation Family Conference features interactive Q&A's, breakout sessions, interactive games, and access to the after party with LGS caregivers.

Register now to participate in the Dravet Syndrome Foundation's Virtual Steps Toward a cure beginning September 19th.

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

Neurology News Network for the week ending September 12, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Mind Moments, a podcast from NeurologyLive, brings you an exclusive interview with Stewart Tepper, MD, in part 1 of this special 3-part multimedia series on the evolution of migraine care.

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Point-of-care, 64mT MRI performs as well as conventional CT and MRI while improving patient safety.

Financial self-efficacy and having at least 1 relapse were identified as independent predictors of financial toxicity among patients with multiple sclerosis.

The chief medical officer at Cure SMA detailed the importance of having options for patients and how certain administration routes and schedules offer more personalized approaches, particularly for adult patients with SMA.

Leah Croll, MD, a neurology resident on the front lines of the COVID-19 pandemic, shares details from her study on the psychosocial impact on physicians and her first-hand experience.

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the CENTAUR open-label extension and AMX0035’s development.

The Project ALS-funded oral MAP4 kinase inhibitor has been described in the literature as an exceptionally potent, metabolically stable, and blood-brain barrier-penetrant compound.

Researchers noted that the findings are encouraging for the use of real-world data and natural history data to augment, or possibly replace, placebo controls in DMD trials.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic highlighted the most pressing needs within the Alzheimer disease community.

Treating patients with super-refractory status epilepticus with ketamine showed no effect on intracranial pressure, cerebral blood flow, and cerebral perfusion pressure.

The chief scientific officer at the Parkinson’s Foundation shares his perspective on the current state of Parkinson research and development amid the challenges of the pandemic.

The neurology resident at NYU Langone described psychosocial implications that physicians faced during the COVID-19 pandemic and the toll it takes on them.

The director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center offers takeaways on hyperbaric oxygen therapy.